Although several studies have examined CIP in the context of PD-1/PD-L1 inhibitors, the specific contribution of CTLA-4 blockade to CIP risk, especially when used in monotherapy or combination regimens remains unclear. This evidence concerns the gene CTLA4 and hereditary sensory and autonomic neuropathy.